» Articles » PMID: 35778747

Next-generation Engineered Nanogold for Multimodal Cancer Therapy and Imaging: a Clinical Perspectives

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2022 Jul 1
PMID 35778747
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is one of the significant threats to human life. Although various latest technologies are currently available to treat cancer, it still accounts for millions of death each year worldwide. Thus, creating a need for more developed and novel technologies to combat this deadly condition. Nanoparticles-based cancer therapeutics have offered a promising approach to treat cancer effectively while minimizing adverse events. Among various nanoparticles, nanogold (AuNPs) are biocompatible and have proved their efficiency in treating cancer because they can reach tumors via enhanced permeability and retention effect. The size and shape of the AuNPs are responsible for their diverse therapeutic behavior. Thus, to modulate their therapeutic values, the AuNPs can be synthesized in various shapes, such as spheres, cages, flowers, shells, prisms, rods, clusters, etc. Also, attaching AuNPs with single or multiple targeting agents can facilitate the active targeting of AuNPs to the tumor tissue. The AuNPs have been much explored for photothermal therapy (PTT) to treat cancer. In addition to PTT, AuNPs-based nanoplatforms have been investigated for combinational multimodal therapies in the last few years, including photodynamic therapy, chemotherapy, radiotherapy, immunotherapy, etc., to ablate cancer cells. Thus, the present review focuses on the recent advancements in the functionalization of AuNPs-based nanoconstructs for cancer imaging and therapy using combinatorial multimodal approaches to treat various cancers.

Citing Articles

Green synthesis, characterization, morphological diversity, and colorectal cancer cytotoxicity of gold nanoparticles.

Akhtar S, Zuhair F, Nawaz M, Khan F RSC Adv. 2024; 14(49):36576-36592.

PMID: 39553281 PMC: 11565694. DOI: 10.1039/d4ra06340f.


Cancer cell membrane-coated siRNA-Decorated Au/MnO nanosensitizers for synergistically enhanced radio-immunotherapy of breast cancer.

Wang D, Lin S, Li T, Yang X, Zhong X, Chen Q Mater Today Bio. 2024; 29:101275.

PMID: 39403312 PMC: 11471673. DOI: 10.1016/j.mtbio.2024.101275.


Combined Photothermal Chemotherapy for Effective Treatment Against Breast Cancer in Mice Model.

Chen J, Xiang Y, Bao R, Zheng Y, Fang Y, Feng J Int J Nanomedicine. 2024; 19:9973-9987.

PMID: 39360036 PMC: 11446203. DOI: 10.2147/IJN.S473052.


A review on selenium and gold nanoparticles combined photodynamic and photothermal prostate cancer tumors ablation.

Omiyale O, Musa M, Otuyalo A, Gbayisomore T, Onikeku D, George S Discov Nano. 2023; 18(1):150.

PMID: 38062330 PMC: 10704013. DOI: 10.1186/s11671-023-03936-z.


Computational Modeling of Gold Nanoparticle Interacting with Molecules of Pharmaceutical Interest in Water.

Fusaro M, Les A, Stolarczyk E, Stolarczyk K Molecules. 2023; 28(20).

PMID: 37894646 PMC: 10609557. DOI: 10.3390/molecules28207167.


References
1.
Choi B, Choi J, Kim U, Hwang D, Kim G . Gold nanoparticles conjugated with programmed death-ligand 1 antibodies induce apoptosis of SCC-25 oral squamous cell carcinoma cells via programmed death-ligand 1/signal transducer and transcription 3 pathway. Arch Oral Biol. 2021; 125:105085. DOI: 10.1016/j.archoralbio.2021.105085. View

2.
Tian J, Gu Y, Li Y, Liu T . CD271 antibody-functionalized HGNs for targeted photothermal therapy of osteosarcoma stem cells. Nanotechnology. 2020; 31(30):305707. DOI: 10.1088/1361-6528/ab8593. View

3.
Nam J, Son S, Ochyl L, Kuai R, Schwendeman A, Moon J . Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018; 9(1):1074. PMC: 5852008. DOI: 10.1038/s41467-018-03473-9. View

4.
Xie J, Gong L, Zhu S, Yong Y, Gu Z, Zhao Y . Emerging Strategies of Nanomaterial-Mediated Tumor Radiosensitization. Adv Mater. 2018; 31(3):e1802244. DOI: 10.1002/adma.201802244. View

5.
Faintuch B, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith C . Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol. 2008; 35(4):401-11. DOI: 10.1016/j.nucmedbio.2008.02.005. View